Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 1,201–1,300 of 1,619
Cancer therapy-related cardiovascular aging: mechanisms, monitoring, and intervention strategies
Lin, X., Wu, Z., Liu, Y., & Liao, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1668623 · Cited by 3
Li, L., Perez, R. L., Shehzad, K., Jennemann, R., Schmidt, C., Walle, T., Tietz-Dahlfuß, A., Grimm, E., Kraske, J. A., Häring, P., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02541-z · Cited by 10
Yang, Q., Xie, C., Luo, Z., Huang, W., Zhang, Z., Ren, K., Xu, X., HE, H., He, M., & Yin, L. (2026) · Redox Report · doi:10.1080/13510002.2026.2632434 · Cited by 4
Cellular Senescence Triggered by Food and Environmental Genotoxins
Kaina, B., Tomicic, M. T., & Christmann, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052389 · Cited by 3
Rheumatoid arthritis-associated interstitial lung disease: A review
David, M., Dieudé, P., Juge, P., et al. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101260 · Cited by 2
The case for space as a model of accelerated aging
Manwaring-Mueller, M., Du, H., Valentino, T. R., Fuentealba, M., Chebykin, A., Wu, F., Furman, D., & Winer, D. A. (2026) · Nature Aging · doi:10.1038/s43587-026-01105-2 · Cited by 3
SenSet defines cell-type specific senescence signatures in the aged human lung
Hasanaj, E., Beaulieu, D., Wang, C., Hu, Q., Rosas, L., Bueno, M., Sembrat, J., Pineda, R., Melo-Narváez, M. C., Cárdenes, N., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00762-8 · Cited by 11
Cheng, J., Aung, C. T. Z., Suslavich, S. F., Sahingur, S. E., & Kapila, Y. L. (2026) · Periodontology 2000 · doi:10.1111/prd.70049 · Cited by 6
Hartono, M., Ge, J., Denholm, M., Ellis, M. G., Henríquez, J. A., Baker, A., Rintoul, R. C., Euser, T. G., Fruk, L., & Muñoz‐Espín, D. (2026) · Nature Aging · doi:10.1038/s43587-026-01116-z · Cited by 2
Senotypes define the diverse landscape of senescent cells
Schafer, M. J., Basisty, N., Hertzel, A. V., Rindone, A. N., Elisseeff, J. H., Suryadevara, V., Aliferis, C., Robbins, P. D., Niedernhofer, L. J., Miller, K. N., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01148-5 · Cited by 7
Self-citationThe Aging Microenvironment in Lung Fibrosis
Deinhardt‐Emmer, S., & Saux, C. J. L. (2022) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-022-00038-3 · Cited by 3
Lu, Q., Han, S., & Liu, X. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.51 · Cited by 2
Zhang, W., Haylock, R., Gillies, M., Hunter, N., & Zhang, E. (2023) · International Journal of Radiation Biology · doi:10.1080/09553002.2023.2187474 · Cited by 2
Moving senolytics closer to the clinic in IPF
Kramer, D., George, G., & Summer, R. S. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104513 · Cited by 3
Chemical constituents with senolytic activity from the stems of Limacia scandens
Lee, H. J., Zhang, M., Doan, T., Park, E. J., Nghiem, D.-T., Pham, H. T. T., Pan, C., & Oh, W. K. (2023) · Phytochemistry · doi:10.1016/j.phytochem.2023.113740 · Cited by 2
-, E. D., & -, D. D. P. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i03.22349 · Cited by 3
Prognostic impact of the combination of p16INK4a, p21 and Immunoscore in rectal cancer
Nakao, T., Shimada, M., Yoshikawa, K., Tokunaga, T., Nishi, M., Kashihara, H., Takasu, C., Wada, Y., & Yoshimoto, T. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02519-x · Cited by 2
Chiu, Y., van Dijk, M. R., Goldschmeding, R., van Laar, J. M., Vries-Bouwstra, J. K. D., & Spierings, J. (2024) · Rheumatology · doi:10.1093/rheumatology/keae660 · Cited by 4
Cellular senescence and PAPP-A
Conover, C. A. (2025) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2025.101637 · Cited by 2
Integrating cuproptosis and immunosenescence: A novel therapeutic strategy in cancer treatment
Firouzjaei, A. A., & Aghaee‐Bakhtiari, S. H. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101983 · Cited by 6
Epigenetic Insights Into Aging: Emerging Roles of Natural Products in Therapeutic Interventions
Pang, Y., Zhang, H., Li, H., Wang, X., Wei, P., Yi, L., & Lin, S. (2025) · Phytotherapy Research · doi:10.1002/ptr.70003 · Cited by 5
Ferrini, E., Bonfini, C., Marchese, G., Buccardi, M., Zoboli, M., Faccioli, P., Sverzellati, N., Villetti, G., Ottonello, S., Ravo, M., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03300-y · Cited by 3
Two roads to fibrosis: Contrasting initiating mechanisms of Bleomycin and TGFβ-1 in lung fibroblasts
D’Alessandro, N., Möbus, L., del Giudice, G., Perho, N., Serra, A., & Greco, D. (2025) · Toxicology · doi:10.1016/j.tox.2025.154233 · Cited by 4
Interstitial Lung Disease in the Elderly: A Review of Pathogenesis and Clinical Management
Patterson, K. C. (2018) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000270 · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
Senolytics Target Senescent Cells and Improve Aging and Age-Related Diseases
Buffard, T., & Ferbeyre, G. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_4 · Cited by 4
Herbal Bioactives for the Treatment of Idiopathic Pulmonary Fibrosis
Sharma, M., Garg, V., & Singh, I. (2021) · Springer eBooks · doi:10.1007/978-981-33-6850-7_15 · Cited by 2
Perspectives to Modify and Counter Aging in the Frame of Subtelomere–Telomere Theory of Aging
Libertini, G. (2022) · OBM Geriatrics · doi:10.21926/obm.geriatr.2204208 · Cited by 2
Haitao, L. I. U., Gong, Y., Nakagawa, M., Tanimoto, H., Yoshikawa, K., Honda, Y., & Yamamoto, K. (2023) · Dental Materials Journal · doi:10.4012/dmj.2022-245 · Cited by 2
Impact of Senolytic Treatment on Gene Expression in Aged Lung
Cho, S. J., Pronko, A., Yang, J., & Stout-Delgado, H. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087628 · Cited by 3
Current mechanisms in the pathogenesis of lung fibrosis
Engin, M. M. N., & Özdemır, Ö. (2023) · Trends in Immunotherapy · doi:10.24294/ti.v7.i1.2028 · Cited by 2
Synergistic Effects of Forskolin and Rutin in the Treatment of Pulmonary Fibrosis in Murine Model
Abdullah, S. M., & Mazumder, P. M. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1158 · Cited by 2
Conover, C. A., Bale, L. K., West, S. A., Oxvig, C., Andersen, K. S., Roden, A. C., & Haak, A. J. (2024) · doi:10.59368/agingbio.20240023 · Cited by 2
Self-citationCavinato, M. S., Wedel, S., & Jansen‐Dürr, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11409-6 · Cited by 3
Elewa, Y. H. A., Ichii, O., Mohamed, S. K. A., & Kon, Y. (2022) · Microscopy and Microanalysis · doi:10.1017/s1431927622000654 · Cited by 2
Protective Mechanisms of Quercetin in Various Lung-induced Injuries
Rizky, W. C., Jihwaprani, M. C., & Mushtaq, M. (2022) · SCIREA Journal of Clinical Medicine · doi:10.54647/cm32844 · Cited by 4
IGFBP2 protects against pulmonary fibrosis through inhibiting P21-mediated senescencePreprint
Chin, C., Lee, J., Ravichandran, R., Fleming, T. P., Wheatcroft, S. B., Kearney, M. T., Bremner, R. M., Mohanakumar, T., Flint, D. J., & Sureshbabu, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.21.427684 · Cited by 2
Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary FibrosisPreprint
Boatz, J. C., Sui, J., Hu, Q., Li, X., Zhang, Y., Königshoff, M., & Kliment, C. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.09.507271 · Cited by 2
The YAP-TEAD complex promotes senescent cell survival by lowering endoplasmic reticulum stressPreprint
Anerillas, C., Mazan-Mamczarz, K., Herman, A. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.18.520921 · Cited by 2
Durik, M., Gonçalves, D. S., Knauer-Meyer, T., Spiegelhalter, C., Messaddeq, N., Seehawer, M., Bulavin, D. V., Zender, L., & Keyes, W. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523642 · Cited by 2
Rad, A. N., Sperger, S., Marsh, L. M., Höetzenecker, K., Lämmermann, I., & Grillari, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.16.623933 · Cited by 3
The Role of p16Ink4a as an Early Predictor of Physiological Decline during Natural AgingPreprint
Tang, L., Hladyshau, S., Ross, A., Nyrop, K. A., Entwistle, A., Muss, H. B., Mitin, N., & Tsygankov, D. (2024) · medRxiv · doi:10.1101/2024.11.21.24317752 · Cited by 2
Modeling the Aging Human Lung: Generation of a Senescent Human Lung Organoid Culture SystemPreprint
Aspal, M., Pushlar, N., Melameka, M., McVicar, R. N., Smith, E., Ogunyamoju, T., Kumar, M., Marth, J. D., Chun, J. J. M., Snyder, E. Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.24.639173 · Cited by 4
An immune-based tool platform for in vivo cell clearance
Zhang, J., Tsukui, T., Wu, X., Brito, A., Trumble, J. M., Caraballo, J. C., Allen, G. M., Zavala‐Solorio, J., Zhang, C., Paw, J. S., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201869 · Cited by 1
Molecular underpinnings of aging contributing to systemic sclerosis pathogenesis
Yang, M. M., Boin, F., & Wolters, P. J. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001061 · Cited by 6
Choi, E., Cho, Y., Kim, M., Jin, H. K., Yoo, Y., Oh, W. K., & Lee, Y. (2024) · Natural Product Sciences · doi:10.20307/nps.2024.30.3.190 · Cited by 1
Physiologische und pathophysiologische Veränderungen der alternden Lunge
Johnsen, M., & Lehmann, M. (2025) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-024-02401-5 · Cited by 1
Hara, D., Sasaki, K., Doi, S., Ike, T., Maeda, K., Yoshida, M., Takahashi, A., Osaki, Y., Ishiuchi, N., Maeoka, Y., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402382r · Cited by 3
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
Metabolic dysfunction over a life course key to healthy ageing inequality
Littlewood, K., Gegic, J., Hickman, M., Henson, R. C. J., Bishop, J. R., Kershaw, T., Diamond, P., Slabaugh, G., Tranos, E., Vasilaki, A., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03034-3 · Cited by 2
Ferreira, R. S., Aires, H. I. R., Rebelo, C., Passos, J. F., Ori, A., Pitrez, P. R., & Ferreira, L. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124117 · Cited by 3
Self-citationSubstrate Stiffness and Viscoelasticity Influence Fibroblast Senescence
Skelton, M. L., Bhat, T., Yu, E., Ofori, A., & Caliari, S. R. (2026) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.70111 · Cited by 3
Exploring the uncharted role of cell senescence in rare diseases
Selvaggio, P., Taci, E., Barassi, A., Massa, V., Gervasini, C., Lesma, E. A., Bernardelli, C., & Fede, E. D. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03778-1 · Cited by 1
Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution
Meridew, J. A., Vu, J. A., Chow, D., Espinosa, A. M. D., Saraf, N., Gao, A. Y., Espíndola‐Netto, J. M., Dresler, S. R., Whaley, M. G., Choi, K. M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00231 · Cited by 2
Self-citationEPDR1 Links Fibroblast Dysfunction to Disease Severity in Idiopathic Pulmonary Fibrosis
Lee, J.-U., Park, S.-L., Kim, M. K., Seo, E.-J., Hwang, H.-G., Kim, J., Chang, H. S., & Park, C. (2025) · Cells · doi:10.3390/cells14191515 · Cited by 1
Davan-Wetton, C. S. A., Khodeneva, N., Denton, C. P., Abraham, D., Perretti, M., & Montero‐Melendez, T. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03635-3 · Cited by 2
Li, X., Yao, W., Cheng, Q., Xiao, S., Yao, S., Yang, D., Wang, J., Chen, L., Li, Q., & Zhan, T. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025206 · Cited by 1
Nyaupane, U., Johannson, K. A., Kelly, M. M., & Kai, F. (2025) · Experimental Lung Research · doi:10.1080/01902148.2025.2582970 · Cited by 1
Mechanisms of aging in the cardiovascular system: challenges and opportunities
Zhao, X., Yang, X., Lin, Y., Lei, R., Ding, W., He, X.-Y., Cao, Y. J., Zhang, D., Liu, P., Liang, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1635736 · Cited by 5
Li, Z., Huan, W., Liu, X., Zhang, K., Wang, X., Huang, Y., Zhou, Q., Huang, S., Sang, Z., & Luo, H. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02407 · Cited by 3
Hughes, J. B., Pujari, A., Sandholm, A., Croll, D., Monk, L. B., Joshua, I., Butterfield, R., Horton, C., Schneider, K., Senchyna, F., et al. (2026) · npj Aging · doi:10.1038/s41514-026-00388-4 · Cited by 4
Metal Ion Metabolism: The Silent Catalyst of Pulmonary Fibrosis
Wan, R., Yan, J., Zhang, W., Fan, W., Liu, Y., & Lin, J. (2025) · The FASEB Journal · doi:10.1096/fj.202502689r · Cited by 1
Provoking myofibroblast death: Strategies to resolve fibrosis and remodel tumor microenvironment
Shalini, T., & Sudhandiran, G. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i12.111086 · Cited by 1
Zhang, W., Xia, T., & Zhang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1697013 · Cited by 1
Zhang, C.-Y., Zhong, W.-J., Yang, J.-T., Qiu, Y.-L., Sha, H.-X., Ou, A.-J., Yu-biao, L., Huang, X., Zhou, Y., Duan, J., et al. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02630-0 · Cited by 1
Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study
Gorini, F., Santoro, M., Pierini, A., Cameli, P., Chimera, D., Lavorini, F., Pistelli, F., Rosi, E., Tavanti, L. M., Tomassetti, S., et al. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04210-y · Cited by 5
Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis
Dong, T., Jiao, X., Wang, H., Gao, Y., Xu, Y., Li, H., Fang, S., Chen, X., Wang, M., Zhu, H., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426723123 · Cited by 2
Climate Change and the Impact On Interstitial Lung Diseases
Ahluwalia, B., & Singh, S. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00347-0 · Cited by 3
The human pathome shows sex and tissue specific aging patterns
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Mediavilla, M. C., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2026) · npj Aging · doi:10.1038/s41514-025-00307-z · Cited by 2
Yamanaka, Y., Tsujimura, Y., Naito, T., Sato, N., Tsukamoto, M., Suzuki, H., Zenke, Y., & Sakai, A. (2026) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.00807 · Cited by 1
Sato, A., 笠原, さ., & Ishigami, A. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70436 · Cited by 1
Ji, J., Crespi, C. M., Yee, L. D., Zektser, Y., Al-Saleem, A., Petersen, L., Lee, C., Son, N., Smith, C. S., Evans, T. S., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261424668 · Cited by 2
Self-citationIntegrative Approaches to Treating Cellular Senescence in Kidney Disease
Misawa, T., Amruta, A., Hickson, L. J., & Wolfram, J. (2026) · Advanced Science · doi:10.1002/advs.202519392 · Cited by 1
Lung mTOR activation leads to lung fibrosis or emphysema via senescence of specific lung cells
Houssaini, A., Marcos, É., Gros, V., Born, E., Abid, S., Rideau, D., Beaulieu, D., Jacquet, J., Lipskaia, L., Gökyildirim, M. Y., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-43628-z · Cited by 3
Epigenetic dynamics of cellular senescence: From mechanistic insights to precision senotherapy
Hu, X., Lai, W., Liu, M., & Wang, B. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004042 · Cited by 2
Lu, H., Cai, L., Lv, D., Sun, G., Lei, J., Ning, T., Xin, Z., Huang, H., Jing, Y., Huang, D., et al. (2026) · Protein & Cell · doi:10.1093/procel/pwag020 · Cited by 3
Miyakawa, K., Oyama, K., Liu, J., Akiyama, N., Sakata, A., Hayashi, M., Kamikokura, Y., Aoki, N., Yuzawa, S., Ichihara, S., et al. (2026) · Current Oncology · doi:10.3390/curroncol33040187 · Cited by 1
NNMT as a therapeutic target in fibrosis: Insights from the heart, liver, kidneys, and lungs
Lai, S.-Y., Ni, X.-L., Bi, S.-Z., Sun, W.-D., Liu, A., Zhang, C., & Li, J.-H. (2026) · Differentiation · doi:10.1016/j.diff.2026.100959 · Cited by 2
Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis
Guo, X., Cao, Y., Liu, L., Peng, Y., Du, Y., Yang, F., & Huang, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103156 · Cited by 1
Cellular senescence: from pathogenic mechanisms to precision anti-aging interventions
Deng, J., Sun, R., Bai, Z., Fang, L., Zhao, X., & Yang, D. (2026) · Aging · doi:10.18632/aging.206375 · Cited by 2
Cellular senescence as a systems-level driver of cardiovascular ageing
Wang, M.-M., Liu, T., Xu, C.-Q., Zhong, Y.-L., Liang, Z.-Q., Li, J., Cao, Y., & Chen, J. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103175 · Cited by 4
The role of lactylation in age-related diseases: a molecular perspective
Li, P., Wu, M., Xu, L., Ji, M., & Guan, H. (2026) · PeerJ · doi:10.7717/peerj.20957 · Cited by 1
Li, Z., Chi, H., Zhu, H., Huang, P., Huang, L., & Lin, W. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3334-8 · Cited by 1
Baurzhan, M. B., Gulyayev, A. E., Absattarova, K. S., Kairgeldina, S. A., Аbzaliyev, K., Izbassarova, A., Lepessova, M., & Absatarova, K. (2026) · Diseases · doi:10.3390/diseases14060201 · Cited by 2
Afzal, B., Tran, V., Nguyen, N., Le, S. Q.-T., Nguyen, T. P., Nguyen, K. T., Liu, L., & Mason, R. P. (2026) · Diagnostics · doi:10.3390/diagnostics16121783 · Cited by 1
Tan, Q., ZHAO, Y., Zhang, Y., Chen, H., Xu, Z., Pan, Z., El‐Khouly, M. E., & Yuan, Y. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09336 · Cited by 4
Miao, Y., Hu, Y. Q., Xu, L., Xu, L., Meng, L., Yang, Y., Liu, Z., Yang, Z., Liu, Y.-M., Liu, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118204 · Cited by 1
Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers
Cai, G., Ren, J., Wang, L., Wu, Y., Wang, H., Cao, X., Shang, H., Hou, X., Wang, Y., Xue, H., et al. (2026) · MedComm · doi:10.1002/mco2.70827 · Cited by 2
Extracellular vesicles in senescence-associated chronic lung diseases
Wang, R., Chen, Y., Liu, X., & Barnes, P. J. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004208 · Cited by 1
Cellular senescence and inflammageing: from mechanisms to senotherapeutic interventions
Chmielewski, P. P. (2026) · Biogerontology · doi:10.1007/s10522-026-10477-2 · Cited by 3
The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis
Rossiello, F., Cicio, G., Sepe, S., Mancheno-Ferris, A., Cancila, V., Castellini, A., Rey, F., Bertolazzi, G., Oppezzo, A., Marinelli, E., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00500-x · Cited by 3
Durik, M., Karout, M., Gonçalves, D. S., Knauer-Meyer, T., Spiegelhalter, C., Messaddeq, N., Seehawer, M., Stephan, P., Bulavin, D. V., Hérault, Y., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.08.002 · Cited by 3
Decline of chaperone-mediated autophagy in aging impairs macrophage clearance of senescent cells
Sereda, R., Lindenau, K. L., Díaz, A., Liu, Z., Santiago‐Fernández, O., Khawaja, R. R., Cutler, R. R., Calyeca, J., McCabe, M., Durand, S., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01240-w · Cited by 4
[Progress on correlation between cell senescence and idiopathic pulmonary fibrosis].
Zhao, S., Zhang, X. Z., & Ke, Y. (2019) · PubMed · doi:10.3785/j.issn.1008-9292.2019.02.16 · Cited by 1
Potential Applications of Aptamers for Targeting Senescent Cells
Leonardi, A., Pacifico, F., & Crescenzi, E. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_10 · Cited by 1
The Pivotal Role of Senescence in Cell Death and Aging: Where Do We Stand?
Sadaf, S., Najm, M. Z., Shingatgeri, V., Uddin, M., Izhari, M. A., Akhtar, S., Kathait, A., Kar, S., Jain, I., Datt, P., et al. (2020) · Current Molecular Biology Reports · doi:10.1007/s40610-020-00129-w · Cited by 1
Regenerative Medicine and the Hope for a Cure
Lehmann, M., & Königshoff, M. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.012 · Cited by 1
Immunesenescence and Compromised Removal of Senescent Cells: Implications for Health in Old Age
Hazeldine, J., & Lord, J. M. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_3 · Cited by 1
Cell senescence is a cause of frailty
Wan, T., Miwa, S., & von Zglinicki, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00013-4 · Cited by 2
The role of targeting cell senescence in vascular diseases and its potential application
Wang, H.-Y., Ding, Y.-N., Wei, Z., Chen, H., & Liu, D. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0279 · Cited by 1
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.